These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36976598)

  • 1. Experiences with Medications for Addiction Treatment Among Emergency Department Patients with Opioid Use Disorder.
    Goldfine CE; Chapman BP; Taylor MM; Bradley ES; Carreiro SP; Rosen RK; Babu KM; Lai JT
    West J Emerg Med; 2023 Feb; 24(2):236-242. PubMed ID: 36976598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting.
    Cisewski DH; Santos C; Koyfman A; Long B
    Am J Emerg Med; 2019 Jan; 37(1):143-150. PubMed ID: 30355476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Brief Educational Intervention to Increase ED Initiation of Buprenorphine for Opioid Use Disorder (OUD).
    Khatri UG; Lee K; Lin T; D'Orazio JL; Patel MS; Shofer FS; Perrone J
    J Med Toxicol; 2022 Jul; 18(3):205-213. PubMed ID: 35415804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
    Carswell N; Angermaier G; Castaneda C; Delgado F
    Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 6. Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone.
    Mannelli P; Douaihy AB; Zavod A; Legedza A; Akerman SC; Sullivan MA
    Am J Drug Alcohol Abuse; 2021 Nov; 47(6):753-759. PubMed ID: 34752714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
    Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
    J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report.
    Szczesniak LM; Calleo VJ; Sullivan RW
    Harm Reduct J; 2020 Oct; 17(1):71. PubMed ID: 33028340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification.
    Uebelacker LA; Bailey G; Herman D; Anderson B; Stein M
    J Subst Abuse Treat; 2016 Jul; 66():48-53. PubMed ID: 27211996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine precipitated opioid withdrawal: Prevention and management in the ED setting.
    Spadaro A; Long B; Koyfman A; Perrone J
    Am J Emerg Med; 2022 Aug; 58():22-26. PubMed ID: 35623179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective Review of a Novel Approach to Buprenorphine Induction in the Emergency Department.
    Dunkley CA; Carpenter JE; Murray BP; Sizemore E; Wheatley M; Morgan BW; Moran TP; Steck A
    J Emerg Med; 2019 Aug; 57(2):181-186. PubMed ID: 31060846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability in opioid use disorder clinical presentations and treatment in the emergency department: A mixed-methods study.
    Faude S; Delgado MK; Perrone J; McFadden R; Xiong RA; O'Donnell N; Wood C; Solomon G; Lowenstein M
    Am J Emerg Med; 2023 Apr; 66():53-60. PubMed ID: 36706482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
    Neighbors CJ; Choi S; Healy S; Yerneni R; Sun T; Shapoval L
    Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):28. PubMed ID: 31238952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers.
    Calcaterra SL; Lockhart S; Callister C; Hoover K; Binswanger IA
    J Gen Intern Med; 2022 Aug; 37(11):2786-2794. PubMed ID: 34981359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.
    Bogan C; Jennings L; Haynes L; Barth K; Moreland A; Oros M; Goldsby S; Lane S; Funcell C; Brady K
    J Subst Abuse Treat; 2020 Mar; 112S():73-78. PubMed ID: 32220414
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.